Where Will Curis, Inc. (CRIS) Stock Go Next After It Is Higher By 22.68% in a Week?

Curis, Inc. (CRIS) stock has risen 22.68% over the past week and gets a Bullish rating from InvestorsObserver Sentiment Indicator.

Curis, Inc. has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on CRIS!

See Full CRIS Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With CRIS Stock Today?

Curis, Inc. (CRIS) stock is higher by 27.24% while the S&P 500 is down -0.05% as of 10:59 AM on Friday, Nov 17. CRIS is higher by $1.61 from the previous closing price of $5.91 on volume of 589,220 shares. Over the past year the S&P 500 has risen 13.82% while CRIS is down -57.97%. CRIS lost -$9.35 per share in the over the last 12 months.

More About Curis, Inc.

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge. Click Here to get the full Stock Report for Curis, Inc. stock.